Dimerix Limited (ASX:DXB) Insider Buys A$57,562.65 in Stock

Dimerix Limited (ASX:DXB) insider Nina Webster acquired 127,917 shares of the company’s stock in a transaction on Friday, January 31st. The stock was acquired at an average cost of A$0.45 ($0.28) per share, with a total value of A$57,562.65 ($36,202.92).

Dimerix Stock Performance

The company has a debt-to-equity ratio of 0.82, a current ratio of 9.49 and a quick ratio of 7.91.

About Dimerix

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. The company develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 which is in phase 2 clinical trial for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology.